-
Mashup Score: 4MRD in AML: Prognosis, treatment, and surrogate endpoints - 2 year(s) ago
In recent years, the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) has been established, and early evidence suggests that MRD analysis may help to guide and personalize treatment decisions.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⏰Catch up with this! 📹During #LLMCongress2021, the #AMLHub was pleased to speak to @kvbesien, @nyphospital. We asked, How do you incorporate MRD into treatment decision-making in clinical practice? 👉 https://t.co/hKlCsdsPq8 👈 #leusm #AMLsm #AML #leukemia https://t.co/ziLLlJeTlT
-
-
Mashup Score: 4MRD in AML: Prognosis, treatment, and surrogate endpoints - 2 year(s) ago
In recent years, the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) has been established, and early evidence suggests that MRD analysis may help to guide and personalize treatment decisions.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔎At the #LLMCongress2021, @RolandBWalter, @fredhutch, provided an update on the status of MRD in the acute myeloid #leukemia setting. 👀 Take a look at the #AMLHub summary here: 👉 https://t.co/C0Y8a0J6Yl 👈 #AML #leusm
-
-
Mashup Score: 1
During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📹During #LLMCongress2021, the #AMLHub was pleased to speak to @kvbesien, @nyphospital. We asked, How do you incorporate MRD into treatment decision-making in clinical practice? 👉 https://t.co/hKlCsdbe1y 👈 #leusm #AMLsm #AML #leukemia https://t.co/OiDkOut0C5
-
-
Mashup Score: 0Treatment strategies for recurrent CLL - 2 year(s) ago
Michael Choi, MD, UC San Diego Health, San Diego, CA, describes the treatment landscape for patients with recurrent chronic lymphocytic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Michael Choi (@UCSDHealth) describes the treatment landscape for patients with recurrent #CLL, inc. the future of targeted and cellular therapies: https://t.co/4dYjGuhArq #LLMCongress2021 #HemOnc #Leukemia #LeuSM #CLLsm #CART #ImmunoOnc
-
-
Mashup Score: 3Metabolomics in myeloma - 2 year(s) ago
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, talks on metabolomics in multiple myeloma, focusing on how our understanding of the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⭐Metabolomics in #Myeloma⭐ @Rfonsi1 (@MayoClinic) discusses the importance of understanding metabolic processes to inform the development of more precise treatments for #MultipleMyeloma: https://t.co/z1rJPzmHwB #LLMCongress2021 #HemOnc #MMsm
-
-
Mashup Score: 0Treating CLL after intolerance or progression on BTKi - 2 year(s) ago
Neil Kay, MD, Mayo Clinic, Rochester, MN, discusses treatment strategies after intolerance to or progression on Bruton’s tyrosine kinase inhibitors…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neil Kay (@MayoClinic) discusses treatment strategies for #CLL after intolerance to/progression on BTKi: https://t.co/y02s2hgWQg #LLMCongress2021 #HemOnc #Leukemia #LeuSM #CLLsm
-
-
Mashup Score: 0Future directions for CAR T-cell therapy in MCL - 2 year(s) ago
Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, explains that Bruton’s tyrosine kinase (BTK) inhibitors continue to be…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CART therapy has gained promised in #MantleCellLymphoma since the approval of second line brexucabtagene autoleucel 💭@VJHemOnc asked @NatalieGroverMD of @UNC_SOM what’s next in this space: https://t.co/GfH8dpVuXc #LLMCongress2021 #HemOnc #Lymphoma #LymSM #MCL #ImmunoOnc
-
-
Mashup Score: 1Key myeloma discussion topics at LLM 2021 - 2 year(s) ago
Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, gives an overview of key discussion topics on…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
❗️Key #Myeloma discussion topics at LLM 2021❗️ @RubenNiesvizky of @WeillCornell and @nyphospital shares his views on the role of MRD and consolidation therapy in #MultipleMyeloma🩸: https://t.co/AZfDezm30B #LLMCongress2021 #mmMRD #MMSM #HemOnc #BMTsm
-
-
Mashup Score: 2ITP update: diagnosis, treatment & COVID-19 vaccines - 2 year(s) ago
James Bussel, MD, Weill Cornell Medicine, New York, NY, gives an update on the diagnosis and treatment of immune thrombocytopenia…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 James Bussel (@WeillCornell) shares the latest updates on the diagnosis, treatment, and COVID-19 vaccination in patients with immune thrombocytopenia 💉🩸 ⬇️⬇️⬇️ https://t.co/tft7N8qU3T #LLMCongress2021 #BleedingDisorders #COVID19 #HemOnc
-
🔔 In case you missed it! At the #LLMCongress2021, @RolandBWalter, @fredhutch, provided an update on the status of MRD in the acute myeloid #leukemia setting. 🔎 Take a look at the #AMLHub summary here: 👉 https://t.co/C0Y8a0J6Yl 👈 #AML #leusm #AMLsm https://t.co/sEO93CsUE4